The ERA Test as a Diagnostic Guide for Personalized Embryo Transfer
Launched by IGENOMIX · Oct 4, 2013
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
This project seeks to investigate differences in implantation (IR), pregnancy (PR), ongoing pregnancy (OP) rates, miscarriages, deliveries (LB) and obstetrical, delivery and neonatal outcomes among women undergoing IVF treatment with own oocytes, at first site appointment (up to 3 previous implantation failures in other sites) and blastocyst stage (day 5 or 6). Patients are allocated through computer-generated randomization into one of the three groups: Fresh embryo transfer (ET), Frozen embryo transfer (FET) or personalized embryo transfer (pET) after identification of the personalized win...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients indicated to undergo a cycle of IVF/ICSI with their own oocytes.
- • 2. Age ≤ 37 years
- • 3. BMI: 18.5 to 30
- • 4. Normal ovarian reserve (AFC ≥ 8; FSH \< 8)
- • 5. The most appropriated stimulation protocol will be decided by their doctor.
- • 6. Blastocyst transfer (on day 5 or 6)
- • 7. Blastocyst vitrification with open protocols (Cryotop, Cryoleaf, or Cryolock) or closed protocols (Cryotip or CBSStraw.)
- • 8. Any pathology affecting the endometrial cavity such as polyps/sub-mucosal myomas, intramural myomas \> 4 cm, or hydrosalpinx affecting the endometrial cavity must be previously operated.
- Exclusion Criteria:
- • 1. Patients with recurrent miscarriages (\> 2 previous biochemical pregnancies or \> 2 spontaneous miscarriages)
- • 2. Patients with a severe male factor (spermatozoa \< 2 million/ml)
- • 3. Patients with implantation failure (\>3 failed cycles with good quality embryos)
- Post-Randomization Exclusion Criteria:
- • 1. Endogenous progesterone level ≥ 1,5 ng/ml at the day of hCG administration in all groups.
- • 2. Absence of blastocysts (day 5 or 6) for embryo transfer.
- • 3. Risk of ovarian hyperstimulation syndrome in any of the three groups and therefore a clinical indication to cancel the transfer cycle where the stimulated patient is from group A (ET).
- • Note: PGT-A is not an inclusion criteria neither an exclusion criteria, therefore those cycles in which PGT-A was performed will be included
About Igenomix
Igenomix is a leading global biotechnology company specializing in reproductive genetics and advanced genomic solutions. Committed to enhancing reproductive health, Igenomix provides innovative testing services that empower individuals and healthcare providers with critical information for informed decision-making in fertility treatments. With a strong emphasis on research and development, Igenomix leverages cutting-edge technologies to deliver accurate genetic assessments, facilitating personalized approaches to reproductive care. The company's dedication to excellence and patient-centric solutions positions it as a trusted partner in the field of reproductive medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, , Spain
Brussels, , Belgium
Campos Dos Goytacazes, Rio De Janeiro, Brazil
Porto Alegre, Rio Grande Del Sur, Brazil
Sao Paulo, , Brazil
Sofia, , Bulgaria
Osaka, , Japan
Panama, , Panama
Leioa, Bizkaia, Spain
Aravaca, Madrid, Spain
Vigo, Pontevedra, Spain
Alicante, , Spain
Barcelona, , Spain
Madrid, , Spain
Sevilla, , Spain
Istanbul, , Turkey
Patients applied
Trial Officials
Carlos Simon, MDPhD
Principal Investigator
IVI Valencia / Igenomix
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials